Recently, Chromai (Beijing) Technology Co., Ltd. (hereinafter referred to as "Chromai") officially announced the completion of a multi-million-yuan Series A+ strategic financing. This round of financing was invested by the well-known domestic healthcare company "Jiuan Medical". This strategic financing will primarily support Chromai in further consolidating its core advantages in independent research and development of mid-to-high-end ultra-high performance liquid chromatography systems, accelerate the process of achieving high-end substitution for Chinese brands in the global market, and, through the expansion of industry-specific solutions and customized offerings, bring far-reaching changes to China's independent R&D-driven high-end scientific instrument market and industry.
Since its establishment in 2019, Chromai, leveraging its profound technical expertise, has rapidly grown into a leading enterprise in the domestic ultra-high performance liquid chromatography (UHPLC) field. Following the core path of "independent R&D," the company has continued to deepen its technological breakthroughs. In 2023, Chromai launched the Frontier UHPLC system, representing a globally advanced level, winning multiple industry awards such as the BCEIA Gold Award and the Antop Domestic UHPLC Excellence Pioneer Award for its cutting-edge technology.
In 2025, Chromai, with its relentless spirit of innovation, once again broke through technical barriers. The newly upgraded ultra-high pressure binary pump UP26T (made of titanium alloy biocompatible material) and quaternary pump UP40, integrating multiple breakthrough technologies, made Chromai the second UHPLC manufacturer in the world to withstand pressures exceeding 20,000 Psi (1380 Bar). This not only elevates domestic UHPLC technology to a globally leading level but also helps usher in a new era of ultra-high efficiency separation in the field of analytical science.
Since the initiation of its commercial layout in 2023, Chromai has demonstrated strong rapid growth in a short period: to date, the company's average annual growth rate exceeds 50%, and its overseas market average annual growth rate has surpassed 80%; it has served hundreds of customers globally, with products exported to more than 20 countries and regions, becoming an important representative of domestic instruments "going global." In its business expansion, Chromai has consistently focused on "industry empowerment and value realization," with its business scope covering key areas such as pharmaceutical analysis, biosynthesis, academic research, food safety, and environmental protection. On one hand, through the localization of high-end equipment, it helps customers significantly reduce procurement costs and improve analysis efficiency; on the other hand, relying on diversified and customized solutions, it continuously expands technology application scenarios, effectively reducing customers' reliance on imported products in terms of supply chain and procurement paths, promoting the construction of an autonomous and controllable industry supply chain.
In terms of commercial layout, Chromai has built a comprehensive commercial system; it is not only one of the few domestic manufacturers with a complete and systematic full-series layout of UHPLC systems but has also created a "full-process solution" covering the fully automated IVD two-dimensional liquid chromatography system, fully automated biological sample pretreatment platform, EyouLab CDS intelligent chromatography data management system, and supporting reagents and consumables. Currently, the localization rate of the company's product components has reached as high as 95%. Leveraging the core advantage of a "fully independent and controllable whole chain," Chromai is continuously deepening the process of domestic substitution, striving to propel Chinese independent scientific instrument brands through the critical transition from "technological breakthrough" to "industrial implementation," injecting robust core momentum into the high-quality development of the entire industry.
Since the founding of Jiuan Medical, I have always held a core belief: truly valuable investment lies not in mere capital accumulation, but in discovering and partnering with pragmatic enterprises that can solve industry pain points and lead industrial upgrading.Chromai is exactly that. Its deep cultivation and breakthroughs in the field of UHPLC have broken the long-standing dependence on imports in this high-end market segment in China, injecting critical momentum into the development of China's independent technology enterprise.
Compared to pure capital injection, I focus more on two core opportunities: First, deepening the 'Stanford model' around independent R&D, fully activating the 'engineer dividend,' and transforming talent advantages into technological breakthrough momentum; Second, seizing the wave of localization of scientific instruments and policy support, rooting in China's efficient supply chain, advancing import substitution in the global market, and achieving cross-cycle growth. Whether it is resource synergy and strategic empowerment, or focusing on layout in key areas of domestic substitution, our core goal is: to activate the value of the 'engineer dividend' with practical measures, helping enterprises overcome technical difficulties; to seize the opportunity of domestic substitution with sustained investment, promoting 'Intelligent Manufacturing in China' to break through 'bottleneck' issues.
I firmly believe that every instance of firm support for technological innovation will converge into a significant force driving China's industrial upgrading and achieving technological self-reliance and self-strengthening, injecting tangible momentum into the implementation of the national independent innovation strategy. I firmly believe that Chromai can continue to innovate in this field and achieve greater substitution breakthroughs in high-end and global scientific instrument domains.
Looking to the future, Chromai will continue to practice its mission of "making analytical testing more efficient, accurate, and accessible." On one hand, it will remain rooted in independent R&D, persistently tackling core key technologies while actively participating in and promoting the construction of industry standards for localization, building a solid "technical foundation" and "standard framework" for the independent development of the high-end scientific instrument field; on the other hand, it will increase its global commercial layout efforts, assisting Chinese independent brands in going global, providing global customers in various application fields with high-quality products and services from Chinese brands, and creating sustained value for customers. In this process, Chromai is even more committed to enabling "Intelligent Manufacturing in China" to gain a greater say in the global testing field, injecting solid strength into the "Healthy China 2030" strategy through practical actions of technological breakthrough and industrial empowerment.